In one embodiment, the present application provides an herbal supplement and method for treating bloating, constipation and/or weight gain in a human subject comprising orally administering to a subject in need thereof an effective amount of the herbal supplement comprising a red quebracho extract. In other embodiments, the supplement may additionally include a triterpenoid saponin, an anti-spasmodic agent, or both.

The invention provides a composition for use as a delivery vehicle comprising at least one thermo-responsive polymer (polymer A) and at least one ion-sensitive polymer (polymer B) in a liquid formulation. Polymer A is preferably a polyoxyethylene-polyoxypropylene block copolymer or a cellulose derivative. Polymer B a polysaccharide. The composition can include an active substance for delivery or can be used as a delivery vehicle for a substance added at the time of administration such as mesenchymal stem cells.

Compositions for treating erectile dysfunction (“ED”), including age related erectile dysfunction (ARED), comprise in a preferred embodiment ginger and an amino acid. Preferably the amino acid is L-arginine and/or L-citrulline. Additionally, the compositions may comprise guarana (Paullinia cupana), Muira puama cortex Magnoliae officinalis (CMO) and/or Fructus aurantil immaturus (FAI). The compositions of the present inventions are administered in a pharmaceutically effective amount to treat erectile dysfunction. Essential ingredients in formulations of the present inventions for treatment of ED and ARED are ginger (or ginger derivative) and L-citrulline or L-arginine. A daily dosage of at least about 250 mg ginger and at least about 400 mg L-citrulline or L-arginine for a sufficient period of time will result in improved IIEF scores in a substantial number of patients.

Compositions for treating erectile dysfunction (“ED”), including age related erectile dysfunction (ARED), comprise in a preferred embodiment ginger and an amino acid. Preferably the amino acid is L-arginine and/or L-citrulline. Additionally, the compositions may comprise guarana (Paullinia cupana), Muira puama cortex Magnoliae officinalis (CMO) and/or Fructus aurantil immaturus (FAI). The compositions of the present inventions are administered in a pharmaceutically effective amount to treat erectile dysfunction. Essential ingredients in formulations of the present inventions for treatment of ED and ARED are ginger (or ginger derivative) and L-citrulline or L-arginine. A daily dosage of at least about 250 mg ginger and at least about 400 mg L-citrulline or L-arginine for a sufficient period of time will result in improved IIEF scores in a substantial number of patients.

Compositions for treating erectile dysfunction (“ED”), including age related erectile dysfunction (ARED), comprise in a preferred embodiment ginger and an amino acid. Preferably the amino acid is L-arginine and/or L-citrulline. Additionally, the compositions may comprise guarana (Paullinia cupana), Muira puama cortex Magnoliae officinalis (CMO) and/or Fructus aurantil immaturus (FAI). The compositions of the present inventions are administered in a pharmaceutically effective amount to treat erectile dysfunction. Essential ingredients in formulations of the present inventions for treatment of ED and ARED are ginger (or ginger derivative) and L-citrulline or L-arginine. A daily dosage of at least about 250 mg ginger and at least about 400 mg L-citrulline or L-arginine for a sufficient period of time will result in improved IIEF scores in a substantial number of patients.

Described herein is a synergistic composition of substances of natural origin, particularly effective in the treatment and prevention of osteoarticular diseases, such as rheumatoid arthritis and osteoarthritis. The composition includes the synergistic combination of aescin, at least one extract of a plant belonging to the genus Boswellia, and an extract of Scutellaria baicalensis. The synergistic composition may be provided in the form of pharmaceutical composition, food supplement, medical device, food for special medical purposes, or a cosmetic.

Described herein is a synergistic composition of substances of natural origin, particularly effective in the treatment and prevention of osteoarticular diseases, such as rheumatoid arthritis and osteoarthritis. The composition includes the synergistic combination of aescin, at least one extract of a plant belonging to the genus Boswellia, and an extract of Scutellaria baicalensis. The synergistic composition may be provided in the form of pharmaceutical composition, food supplement, medical device, food for special medical purposes, or a cosmetic.

Described herein is a synergistic composition of substances of natural origin, particularly effective in the treatment and prevention of osteoarticular diseases, such as rheumatoid arthritis and osteoarthritis. The composition includes the synergistic combination of aescin, at least one extract of a plant belonging to the genus Boswellia, and an extract of Scutellaria baicalensis. The synergistic composition may be provided in the form of pharmaceutical composition, food supplement, medical device, food for special medical purposes, or a cosmetic.

Embodiments herein include a composition that can include one or more saponins and one or more non-pathogenic bacterial strains. In an embodiment, a method of treating an animal to reduce the bactericidal effect of protozoa is included. The method can include administering a composition comprising saponins and administering a composition comprising at least 1×10.sup.7 colony forming units (CFU) per gram of one or more bacterial strains. The saponins can reduce a bactericidal activity of protozoa within the animal on the one or more bacterial strains. Other embodiments are also included herein.

Embodiments herein include a composition that can include one or more saponins and one or more non-pathogenic bacterial strains. In an embodiment, a method of treating an animal to reduce the bactericidal effect of protozoa is included. The method can include administering a composition comprising saponins and administering a composition comprising at least 1×10.sup.7 colony forming units (CFU) per gram of one or more bacterial strains. The saponins can reduce a bactericidal activity of protozoa within the animal on the one or more bacterial strains. Other embodiments are also included herein.